Preclinical Efficacy of Novel Dual PI3K/mTOR Inhibitor CMG002 As Potential Anti-Hepatocellular Carcinoma Agent

被引：0
|
作者：
Kim, Mi Na [1 ]
Lee, Seung Min [2 ]
Hwang, Seong-Gyu [3 ]
机构：
[1] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Pochon, South Korea
[2] CHA Univ, CHA Bundang Med Ctr, Inst Clin Res, Pochon, South Korea
[3] Cha Bundang Med Ctr, Seongnam, South Korea
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2233
引用
收藏
页码：1266A / 1266A
页数：1
相关论文
共 50 条
  • [31] The dual PI3K/mTOR inhibitor, PI-103, demonstrates therapeutic efficacy in undifferentiated pleomorphic sarcoma
    Zhu, Quansheng
    Xie, Xianbiao
    Nguyen, Theresa
    Bolshakov, Svetlana
    Pollock, Raphael E.
    Lev, Dina Chelouche
    CANCER RESEARCH, 2011, 71
  • [32] Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
    Bang, Jieun
    Jun, Mihyeon
    Lee, Soyun
    Moon, Hyuk
    Ro, Simon Weonsang
    PHARMACEUTICS, 2023, 15 (08)
  • [33] Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma
    Doghman, Mabrouka
    Lalli, Enzo
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2012, 364 (1-2) : 101 - 104
  • [34] The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
    Tian, Ling-Yu
    Smit, Daniel J.
    Juecker, Manfred
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [35] Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma
    Chi Hang Wong
    Herbert H. Loong
    Connie W. C. Hui
    Cecilia P. Y. Lau
    Edwin P. Hui
    Brigette B. Y. Ma
    Anthony T. C. Chan
    Investigational New Drugs, 2013, 31 : 1399 - 1408
  • [36] Preclinical efficacy of the novel dual PI3K/mTOR inhibitor, BEZ235 compared with RAD001 in HER2+breast tumors
    De, Pradip K. R.
    Sun, Yuliang
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2011, 71
  • [37] Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma
    Wong, Chi Hang
    Loong, Herbert H.
    Hui, Connie W. C.
    Lau, Cecilia P. Y.
    Hui, Edwin P.
    Ma, Brigette B. Y.
    Chan, Anthony T. C.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1399 - 1408
  • [38] PRECLINICAL STUDIES OF THE PI3K/MTOR DUAL INHIBITOR, PF-04691502, IN BREAST CANCER CELL LINES
    Kan, J.
    Yuan, J.
    Lee, N.
    Pavlicek, A.
    Ching, K.
    Cao, J.
    Garza, S.
    Hook, K.
    Christensen, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 55 - 55
  • [39] Preclinical PKPD modeling and human dose projection of PF-046915027, a PI3K/mTOR dual inhibitor
    Luu, Kenneth T.
    Zhang, Eric
    Bagrodia, Shubha
    Yuan, Jing
    CANCER RESEARCH, 2010, 70
  • [40] Early preclinical development of PQR309, a novel balanced dual PI3K/mTOR inhibitor for treatment of various cancer types
    Ettlin, R.
    Dieterle, W.
    Fabbro, D.
    Hebeisen, P.
    Beaufils, F.
    Hillmann, P.
    Stumm, M.
    Dimitrijevic, S.
    Wymann, M.
    Cmiljanovic, N.
    Giese, B.
    Cmiljanovic, V.
    TOXICOLOGY LETTERS, 2015, 238 (02) : S337 - S338
12345